Physician profile
Catherine Vanderloos
NPI 1588840888
$54,808.83
in general payments reported to CMS, 2019-2025
22 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $1,139 · 2021: $2,019 · 2022: $10K · 2023: $2,049 · 2024: $449 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,590 · Food and Beverage: $901 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,590.00 |
| Food and Beverage | $901.00 |
| Education | $113.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $24,308.71 | 2019 | |
| Coopersurgical, INC. | $14,141.85 | 2019-2025 | Endosee, Mara Console, Wallach Cryosurgical Equipment |
| Lupin INC. | $14,073.95 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $353.74 | 2019-2024 | Contrave |
| Abbvie INC. | $340.67 | 2019-2022 | |
| Evofem Biosciences, INC. | $324.29 | 2020-2023 | Phexxi |
| Astellas Pharma US INC | $243.17 | 2019-2024 | Veozah |
| Pfizer INC. | $185.82 | 2019-2023 | |
| Novo Nordisk INC | $124.54 | 2019-2023 | Wegovy |
| Allergan, INC. | $109.64 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $80.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.02 | 2019-2021 | |
| Eisai INC. | $63.57 | 2020-2021 | |
| Millicent US INC | $63.33 | 2021-2024 | Intrarosa |
| Vertical Pharmaceuticals, LLC | $61.25 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $59.23 | 2023-2024 | Quviviq |
| Hologic Sales and Service, LLC | $48.91 | 2019-2020 | |
| Axonics, INC. | $45.23 | 2020 | |
| Therapeuticsmd, INC. | $31.22 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $29.15 | 2024 | Gemtesa |
| Scynexis, INC. | $25.94 | 2022 | |
| Merz North America, INC. | $18.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Vanderloos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.